Osmetech acquired the Opti product line from Roche Diagnostics. Opti is the portable analysis technology for bloodgas and electrolytes measurement. This highly successful analyser has also taken the veterinary world by storm. IDEXX Laboratories Inc (IDXX) have entered into a ten year OEM agreement to provide the customised OPTI analysers to the veterinary field under the brand VetStat.

In September 2004 the company acquired the "OPTIgene" (Genedrive) product from MS this technology will enable OMH a strong entry point into the fastest growing market segment of DNA based diagnostics. A market that is growing at an annual rate of 20% and is currently worth $ 22 bln !

In the latest acquisition 1/7/05 Osmetech acquired Clinical Micro Sensors from Motorola PLC, OMH plans to utilise the eSensor technology coupled with OPTIgene to address the majority of existing and new tests in the genetic diagnostics market. 'CMS's diagnostic tests for cystic fibrosis and CYP450 are closest to commercial launch and OMH believes that these products have significant market potential.

Scroll & Click for Websites & Other LinksRT Mag Wall Street Reporter Interviews JW

Up Coming Events in 2006

CMS CYP450 product Launch!!!!!............................................. 2006

IDEXX critical care platform Launch!!!!!....................................2006/7....much more to follow

Click Here to Track Osmetech's Progress in the "Stocks That Could Double in 2006" Competition

Ditchpig..are you sure?

Results are out.....can anyone post results or link for others. Results as expected for me but sp dropping. Bringing new products to the market is expensive, so always going to need additional funding. DYOR and dont listen to rampers like Bangersmam and his posts on other sites. Substantial rise get real. Sound management establishing a good solid platform for growth never going to be a quick buck made here. I continue to hold.

As a holder of this stock for over four years, I'm very glad I sold out at the recent peak of around 34p (nursing a chunky loss, too). I'm afraid to say that I have been disappointed with this share since the "story" changed quietly some time back from selling a Chlamydia test based on the "electronic nose technology" into a multi-billion-dollar market to the current concentration on Gene products. (The Chlamydia product appears to have been rendered superfluous by a home-testing product developed by a rival; it's a pity OMH didn't see this coming sooner). A lot of dilution has been involved in the process of OMH acquiring new products and for those of us who bought most of our stock pre-consolidation, that has meant that the attractiveness of the share has dwindled greatly over time. While I am certain that OMH's new product range will have its day in the sun, it is clear that a lot more dilution is in the pipeline as they place stock in order to fund the co through to profitability.

This share would have to take a well-deserved hammering before I could be induced to buy again. Perhaps a visit to the recent low of around 15p is too much to ask, but I would only think of the SP as attractive around 18p and then as a speculative bet rather than a near certainty. Longer-term I'd incline towards agreeing with astonvilla, but so far it has been a bumpy ride and more than likely will be in the future.

All IMHO, PDYOR, etc., and good luck to those of you who are still in!!

Like Soul traders, I have been in this stock for a few years, hoping with some enthusiam that their products were at the forefront of technology and rich pickings were there for the brave.

Trouble is that the management keep moving the goalposts promising jam tomorrow and continually look for acqusitions without fully bedding down previous buys. Perhaps the markets reaction today will remind the management that it is a fickle world out there and they will be continually penalised in the SP when they dont deliver.

Good comment, hobbsts - hope you haven't bet your pension fund on this one!! :o)

What a group of pathetic, short sighted, moaning, old whingebags.



Yes the company has stated they may require further funding to take them in to profit BUT they have also made clear this may come from a variety of ways. NOT necessarily by further dilution of the SP.

As for not bedding in previous acquisitions??? I think we can now say OPTI is firmly bedded in with the help of a 10 year agreement with IDEXX, and the recently purchased MOLs and CMS technology is only a few months away from hitting the market in it new form...... The same technology which is currently being applied to a new platform at IDEXX which will be an instant worldwide hit to be launched in the short / medium term. Not to mention the chance of the technology being used in alternative markets - forensics, environmental etc...........................zzzzzzzzzzzzzzzzzzzzz

For those that haven't bothered to read further than the results headlines - News flow over the next few months will be very strong.

1) CMS eSensor - launch date: April 2006
2) OPTI TUBE - launch date: May 2006
3) OPTI GENE - launch date: June 2006

These products were exhibited in
November 2005 at two major international shows in the US (AMP) and Europe
(Medica) and generated a significant level of pre-launch interest both from
potential commercial partners and end customers.

Nope - thank god for my final salary pension!!

Am showing a hefty loss on Osmetech and have put it down to experience .... you win some , you lose some. Will hold in the forlorn hope that the management can find some profit within their little empire, but the continued promise of success has worn very thin with me, but I least I still can have a giggle every time they release their results !!!

I think it is a shame Bangersmam when you have some investors who share a different view to yours you have to call them pathetic..Who was the one that mentioned a significant rise a few days ago?..ummm grow up. I'm not disputing what you say but you ramp a share too much here and on a competitor board. The last few posts by observers and investors are well judged there are no quick bucks here but I for one also remain positive about the future albeit not as quick as we would all like.

Yaaaawwwwwwwwwn

The lunch time AFX update


LONDON (AFX) - British diagnostics group Osmetech PLC reported widening
losses in the last 8 months of 2005 after buying molecular diagnostics group
Clinical Micro Sensors (CMS) last year.
Osmetech is reporting 8 month results after changing its year end date. In
the 8 months ended Dec 31 pretax losses widened to 5.4 mln stg from a loss of
2.9 mln in the 12 months ended April 30, 2005.
CMS accounted for 2.9 mln stg of the losses, and Osmetech said group loss
will increase this year reflecting a full year's effect of the new business.
The company is due to launch three new products in the next few months, and
chief executive James White told AFX News that profitability should start to
improve as soon as they hit the market.
"We knew when we bought the business we would have to fund some working
capital, but within 6 months we've got a product ready to hit the market place,"
he said in an interview.
Osmetech has two units, critical care, which makes blood gas analysis
machines, and another that is developing molecular diagnostics equipment.
It was the latter division that was strengthened with the acquisition of CMS
last year. Its first test, to detect the gene for Cystic Fibrosis, will be
launched shortly on the new eSensor platform.
A DNA analysing system called Opti Gene and a product line for use on a
Roche AG instrument will follow.
Osmetech hopes smaller hospitals will buy the machines. They allow doctors
to carry out tests on site and more cheaply than sending away samples to a lab.
White said the market for molecular diagnostics is growing fast as more
tests are developed, and the division has the potential to be more profitable.
The distribution network already established for the critical care business
will be utilised to roll out the new products.
The group will also be looking to acquire and develop new tests, such as for
MRSA detection, the CEO added.
In the last 8 months of 2005, sales surged 78 pct to 5.59 mln stg compared
to the same period the previous year. The result was lifted by a
better-than-expected result from Critical Care.
The launch of a new machine for vets helped boost sales in 2005 by 64 pct to
14.79 mln usd. The company is not anticipating the same level of growth from the
division this year, but sales should still increase significantly and
profitability improve, it predicted.
Osmetech shares were trading 3 pence weaker at 22.25 at noon, valuing the
company at 33 mln stg.
amy.brown@afxnews.com
ab/vjt/ab/ra

COPYRIGHT

clueless tw@ts

Its the market that ultimately judges the company by its performance and future outlook. I would absolutely love OMH to rocket and make me some money, but I think people have to be realistic and not to get carried away with the jam tomorrow syndrome.

exactly Hobbsts you only have to view AD VFN message board to see what Ditchpig and Bangersmam post......if anybody is clueless its them. They abuse and ridicule people who dare to have a slightly different opinion to themselves......so what is the point of investor threads if it is not for debate, either positive or negative. i feel quite sorry for them as I have far better things to do than call people clueless ***** and pathetic. The more OMH posts here the better as I am sure Moneyam will not let this site get as abusive as AD VFN. Sorry to say like most things it is a few people that spoil it for the rest of us.

bangersmam,

not shortsighted, just opening up the debate a little. As I have said, I could be persuaded to buy more OMH, but only if I think I can see significant upside, and more than in the many other stocks I am also watching.

Ditchpig,

You'll notice that I don't make personal comments; I'm here to talk about shares. Ten-baggers, preferably.

And I'll thank you for minding your language.

Usual sell off after the results, the small short sighted PI's sell and the big boys buy. I dont think it will be long before an increased holdings RNS comes out.

My guess is that Gartmore have been loading up. Time will tell.

Presumably you were driven out of Bournemouth with pitchforks and flaming torches. Arrrr don't want none of those namby pamby 'omosexual types 'ere.

Actually it was electric cattle prods - the farmers down in Dorset aren't as backward as they're made out to be.

LOL!
arrr don't be messin wiv this ere new fangled lectric. It be witchcraft I'll tell thee.

So its confirmed - Gartmore WERE buying the shares from the likes of the above shortsighted ones.

SAR 3 - Osmetech plc

FORM SAR 3

DISCLOSURE OF ACQUISITIONS

(Rule 3 of The Rules Governing Substantial Acquisitions of Shares)

Name of acquirer Gartmore Investment Management plc

Beneficial owner, if different (Investments managed on a discretionary
from above basis)

Names of any other persons
acting by agreement or
understanding (see SAR 5)

Company dealt in Osmetech plc

Class of voting shares (eg Ordinary GBP0.001
ordinary shares)

Date of acquisition 22nd March 2006

Number of shares acquired 1,700,000

Number of rights over shares
acquired

Nature of rights over shares

Total holding of voting shares 24,084,657 (18.27%)
(and percentage of total voting
shares in issue)

Total holding of rights over
shares (and percentage of total
voting shares in issue)

Combined total holding (and 24,084,657 (18.27%)
percentage) of voting shares and
rights over shares